Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash & Cash Equivalents | $9,222.0K | $18.8M | $24.1M | $16.5M | $2,145.0K | $12.7M | $10.7M | $14.8M | $90.8M | $113.9M | $159.2M | $282.9M | $162.6M | $381.2M | $495.1M | $487.4M | $532.8M | $716.8M | $1,074.0M | $482.4M |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Insmed Incorporated's last 12-month Cash & Cash Equivalents is $555.0M, based on the financial report for Dec 31, 2024 (Q4 2024).
Over the last year, Insmed Incorporated's Cash & Cash Equivalents growth was 15.1%. The average annual Cash & Cash Equivalents growth rates for Insmed Incorporated have been (15.8%) over the past three years, 2.6% over the past five years.
Over the last year, Insmed Incorporated's Cash & Cash Equivalents growth was 15.1%, which is higher than industry growth of (0.1%). It indicates that Insmed Incorporated's Cash & Cash Equivalents growth is Good.